Valuation: Satellos Bioscience Inc.

Market Cap 15Cr 14Cr 12Cr 11Cr 21Cr 1.43TCr 22Cr 150.48Cr 60Cr 763.92Cr 57Cr 56Cr 2.41TCr P/E 2026 *
-3.05x
P/E 2027 * -2.97x
Enterprise Value 5.07Cr 4.55Cr 4.16Cr 3.79Cr 7.15Cr 476.62Cr 7.37Cr 50Cr 20Cr 254.31Cr 19Cr 19Cr 802.84Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.63%
Yield 2026 *
-
Yield 2027 * -
1 day+0.30%
1 week+12.15%
Current month+6.39%
1 month-5.23%
3 months-26.71%
6 months+1.50%
Current year+28.16%
1 week 8.65
Extreme 8.65
10.49
1 month 8.65
Extreme 8.65
10.7
Current year 7.67
Extreme 7.67
18.98
1 year 7.56
Extreme 7.560003
18.98
3 years 3.48
Extreme 3.480001
18.98
5 years 2.58
Extreme 2.580001
18.98
10 years 2.58
Extreme 2.580001
22.8
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2018
Chief Tech/Sci/R&D Officer - 01/05/2018
Director of Finance/CFO - 01/09/2023
Director TitleAgeSince
Chairman 59 01/07/2018
Director/Board Member 50 01/03/2018
Director/Board Member 70 01/07/2012
Date Insider Type Main position Quantity % Market Cap. Importance
18/08/26 Option

Director

10,608 0.0509%
18/08/26 Option

Director

10,608 0.0509%
18/08/26 Option

Director

10,608 0.0509%
Change 5-day change 1-year change 3-year change Capi.($)
+0.30%+12.15%+11.29%+168.52% 15Cr
+2.24%+5.83%+58.47%+65.65% 6.67TCr
+4.24%+8.49%+14.14%+84.71% 5.69TCr
-0.11%+2.34%+24.23%+95.58% 5.65TCr
+2.28%+14.95%+26.15%+119.09% 4.65TCr
+1.50%+6.59%+29.30%+43.55% 4.48TCr
+2.48%+5.06%+215.14%+887.44% 4.16TCr
-0.47%+9.60%+27.53%+52.88% 3.53TCr
+3.80%-1.00%+95.20%+66.79% 3.33TCr
+0.24%+4.87%-40.27%+389.45% 2.51TCr
Average +1.68%+3.57%+46.12%+197.36% 4.07TCr
Weighted average by Cap. +1.94%+3.97%+50.83%+179.14%

Financials

2026 *2027 *
Net sales - -
Net income -4.99Cr -4.48Cr -4.09Cr -3.74Cr -7.04Cr -469.25Cr -7.26Cr -49Cr -20Cr -250.38Cr -19Cr -18Cr -790.44Cr -6.55Cr -5.88Cr -5.37Cr -4.9Cr -9.23Cr -615.76Cr -9.53Cr -65Cr -26Cr -328.56Cr -25Cr -24Cr -1.04TCr
Net Debt -10Cr -9.11Cr -8.33Cr -7.6Cr -14Cr -955.06Cr -15Cr -100.38Cr -40Cr -509.6Cr -38Cr -37Cr -1.61TCr -12Cr -11Cr -9.75Cr -8.9Cr -17Cr -1.12TCr -17Cr -117.57Cr -47Cr -596.88Cr -45Cr -44Cr -1.88TCr
Projected Income Statement - Annual - Satellos Bioscience Inc.
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
09/26/09 CA$10.15 +0.30% 2,715
06/26/06 CA$10.12 +12.20% 29,021
05/26/05 CA$9.020 -3.11% 34,191
04/26/04 CA$9.310 +3.44% 401
03/26/03 CA$9.000 -0.55% 7,819
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Satellos Bioscience Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
10.12CAD
Average target price
17.47CAD
Spread / Average Target
+72.66%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Satellos Bioscience Inc.
  1. Stock Market
  2. Stocks
  3. MSCL Stock